NORTH AMERICAN NEUROENDOCRINE TUMO… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2007

Legal Domicile

Principal Officer

JENNIFER CHAN

Phone

6507626387

Tax Period

2024-01-01 to 2024-12-31

NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY, founded in 2007, is a community nonprofit in the Medical Research sector that reported $1.2M in total revenue in fiscal year 2024. Revenue grew 11% year-over-year, indicating healthy expansion.

Mission

TO IMPROVE NEUROENDOCRINE TUMOR DISEASE MANAGEMENT THROUGH INCREASED RESEARCH AND EDUCATIONAL OPPORTUNITIES

Program Service Accomplishments

Program 1

Expenses: $317,013 Revenue: $4,720

CONTINUING MEDICAL EDUCATION. PREVIOUSLY CONSIDERED A RARE DISEASE, NEUROENDOCRINE TUMORS HAVE NOW BEEN WELL DOCUMENTED AND DATA SUGGESTS THAT THE DIAGNOSED INCIDENCE IS INCREASING.

Program 2

Expenses: $670,111 Revenue: $931,521

ANNUAL SYMPOSIUM FOR NEUROENDOCRINE TUMOR RESEARCH

Program 3

Expenses: $169,176 Revenue: $0

OTHER RESEARCH AND EDUCATION PROJECTS

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $217,283

Program Service Revenue $936,241

Investment Income $51,590

Other Revenue $0

TOTAL REVENUE $1,205,114

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $1,156,300

Other Expenses $1,300,312

TOTAL EXPENSES $1,300,312

Year-over-Year Comparison

	2024	2023	Change
Revenue	$1,205,114	$1,085,991	+0.1%
Expenses	$1,300,312	$1,370,132	-0.1%
Net Income	$-95,198	$-284,141	-0.7%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JENNIFER CHAN	PRESIDENT	4.00	Officer Director	$0	$0	$0
SIMRON SINGH	VICE PRESIDENT	4.00	Officer Director	$0	$0	$0
ARVIND DASARI	TREASURER	4.00	Officer Director	$0	$0	$0
CALLISIA CLARKE	SECRETARY	4.00	Officer Director	$0	$0	$0
THORVARDUR HALFDANARSON	PRES EMERITA	4.00	Officer Director	$0	$0	$0
TAYMEYAH AL-TOUBAH	DIRECTOR	2.00	Director	$0	$0	$0
ALEXANDRA GANGI	DIRECTOR	2.00	Director	$0	$0	$0
JULIE HALLET	DIRECTOR	2.00	Director	$0	$0	$0
DANIEL HALPERIN	DIRECTOR	2.00	Director	$0	$0	$0
THOMAS HOPE	DIRECTOR	2.00	Director	$0	$0	$0
RENUKA IYER	DIRECTOR	2.00	Director	$0	$0	$0
ERIK MITTRA	DIRECTOR	2.00	Director	$0	$0	$0
JANICE PASIEKA	DIRECTOR	2.00	Director	$0	$0	$0
ROBERT RAMIREZ	DIRECTOR	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$1,205,114	$1,300,312	$1,474,202	$-95,198
2023	$1,085,991	$1,370,132	$1,504,249	$-284,141
2022	$1,287,018	$1,220,534	$1,938,390	$66,484
2021	$777,591	$490,327	$1,880,427	$287,264
2020	$669,754	$367,604	$1,321,227	$302,150
2019	$1,175,415	$862,237	$1,018,755	$313,178
2018	$1,016,150	$1,120,441	$705,376	$-104,291
2017	$868,896	$922,482	$804,605	$-53,586

NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY